Context Therapeutics Inc.

Context Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Philadelphia, Pennsylvania, dedicated to advancing T cell engaging (TCE) bispecific antibodies for the treatment of solid tumors. The company's mission is to improve outcomes for patients facing difficult-to-treat cancers by developing innovative immunotherapeutic solutions.

The company's pipeline focuses on next-generation TCE bispecific antibody therapies, including CTIM-76 (Claudin 6 x CD3), CT-95 (Mesothelin x CD3), and CT-202 (Nectin-4 x CD3). These product candidates are designed to redirect a patient's own T cells against cancer cells in various solid tumor indications, such as ovarian, endometrial, lung, pancreatic, breast, and bladder cancers.

Recent developments include the company's addition to the Russell 2000® and Russell 3000® Indexes in July 2026. Context Therapeutics also announced positive interim efficacy and safety results from an ongoing Phase 1 clinical trial for CTIM-76 in June 2026, and CTIM-76 has received FDA Fast Track Designation for the treatment of platinum-resistant ovarian cancer. Led by Co-Founder, President, and CEO Martin A. Lehr, the company anticipates its cash and cash equivalents will fund operations into mid-2027.